René Csuk, Christian Raschke, Gunnar Göthe, Stefan Reißmann

Institut für Organische Chemie, Martin-Luther-Universität Halle-Wittenberg, D-06120 Halle (Saale), Germany

Synthesis of Dimeric Trifluoromethoxyacridinederived Pathogen-inactivating Nucleic Acid Intercalators

A series of antiviral active compounds consisting of an intercalating acridinederived part, a spacer region and a reactive EDTA-derived conjugate was synthesized in an easy sequence. Thus, suitably mono-protected 1, ω -alkyldiamines gave, upon reaction with 9-chloro-2-trifluoromethoxyacridine, followed by deprotection and reaction with EDTA dianhydride, the target molecules. Incorporation of their Fe(II) complexes in the presence of ascorbate gave a reduction of the phage titer of MS2 phages by several logarithmic decades.

Keywords: Pathogen Inactivation; Nucleic Acid Intercalators; Acridine

Received: June 11, 2004; accepted: September 2, 2004 [FP907] DOI 10.1002/ardp.200400907

Introduction

The safety of blood and plasma is the subject of an ongoing concern among the public, underlining the need for the development of efficient analytical systems as well as of anti-pathogenic drugs. Life-threatening diseases can be the result of accepting blood or plasma donations if they carry viral infectious agents. The potential bioburden of the donated blood has to be minimized, but this goal cannot completely be achieved by simple testing of blood and plasma donations for the presence of infectious agents, since it is not possible to perform assays against all known and unknown biological threats. Thus, the development of anti-pathogenic measures seems to be called for.

Results and discussion

Quite recently [1], a new type of pathogen-inactivating agents (type **A**; Figure 1) was introduced, consisting of an intercalator that binds to the nucleic acid of pathogens combined with a conjugate that subsequently destroys the nucleic acid via a Fe(II)-mediated Fenton mechanism. The latter process accomplishes damage to the nucleic acids by producing OH radicals. Since the metal attached to the conjugate can change between two levels of oxidation, a cycle can finally be constructed in the presence of suitable reduction agents (*e.g.* ascorbic acid) that increases



Figure 1. Types of anti-pathogenic compounds.

the damage to the biological molecules. Thus, the reactivity of the molecules can be triggered by the presence and the concentration of a more or less harmless agent.

Of paramount importance is the interaction of the intercalator with the nucleic acids. Thus, it can safely be assumed that dimeric structures (type **B**; Figure 1) should provide a better intercalation and thus a higher anti-pathogenic activity. From preliminary modelling studies we deduced that the presence of a 2-trifluormethoxy moiety in the acridine ring should result in an improved interaction between the intercalator and the nucleic acids.

From a palladium-assisted Buchwald-Hartwig amination reaction between methyl 2-iodobenzoate and 4-trifluoromethoxyaniline [2], methyl 2-[4-(trifluoromethoxy)amino]benzoate [3] was obtained. Saponification followed by a POCl₃-mediated cyclization furnished the starting material for our sequence,

Correspondence: René Csuk, Institut für Organische Chemie, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Straße 2, D-06120 Halle (Saale), Germany; Phone: +49 345 5525660, Fax: +49 345 5527030, e-mail: csuk@chemie.uni-halle.de



Scheme 1. Syntheses of the target molecules. Reagents: a) phenol; b) aq. HCl; c) EDTA dianhydride.

9-chloro-2-trifluoromethoxyacridine (1) (Scheme 1). Reaction of 1 with monoprotected diamines, 1-aminox-tert-butyloxycarbonylaminoalkanes 2 [4], 3 [5], 4 [6], 5 [7], 6 [8], 7 [9] or 8 [10] in phenol [11, 12] gave the acridinyl carbamates 9-15, respectively. These acridinyl carbamates were deprotected using aqueous hydrochloric acid to afford the corresponding bishydrochlorides 16-22. These compounds were allowed to react with EDTA dianhydride to yield the target compounds 23-29 (Scheme 1).

For biological screening, the compounds were loaded with three equivalents of Fe(III) and then incubated in Tris buffer with MS2 phages [13], in the presence of sodium ascorbate. Whereas almost no anti-pathogenic acivity was observed in the absence of ascorbate, in the presence of ascorbic acid the phage titer of the MS2 phages was reduced by several logarithmic decades (Figure 2). As compared to monomeric, unsubstituted acridine analogues [1] or to the photoinactivation by porphyrins [14], an approximately 100fold higher anti-pathogenic activity could be achieved.

Modifications in the structure of these compounds, as well as an extended biological screening, are presently performed in our laboratories.

Acknowledgments

Thanks for helpful discussion and parts of the biological screening are due to Dr. H. Knoller and Dr. H.-J.



Figure 2. Inactivation of phage MS2 as a function of spacer length [20 °C, 5 mmol Na-ascorbate, 100 μ M of compounds 23–29 (Fe³⁺ loaded, 3 equiv.)].

Arch. Pharm. Pharm. Med. Chem. 2004, 337, 571-578

Neumann (Fresenius Hemocare); additional screening has been performed by Bioscreen Ltd. Financial support, by the European Communities (SC1-CT92-0780) and the Fonds der Chemischen Industrie, is gratefully acknowledged. We like to thank Dr. D. Ströhl for numerous NMR spectra, Dr. R. Kluge for the MS spectra, Mr. T. Brezesinski and Ms. B. Janeska for her help in the preparation of starting materials.

Experimental

General

Melting points are uncorrected (Leica hot-stage microscope). NMR spectra were recorded using the Varian spectrometers Gemini 200, Gemini 2000 or Unity 500 (δ given in ppm, J inHz, internal Me₄Si); IR spectra (film or KBr pellet) were recorded on a Perkin-Elmer FT-IR spectrometer Spectrum 1000; MS spectra were taken on a Intectra GmbH AMD 402 (electron impact, 70 eV) or on a Finnigan MAT TSQ 7000 instrument (electrospray, voltage 4.5 kV, sheath gas nitrogen). For elemental analysis, a Foss-Heraeus Vario EL instrument was used. TLC was performed on silica gel (Merck 5554); detection by UV absorption or by treatment with a solution of 10% sulfuric acid, ammonium molybdate and cerium^(IV) sulfate, followed by gentle heating. The solvents were dried according to usual procedures.

Bacteriophages and screening

The effect of the compounds on bacteriophages was tested on bacteriophages MS2 grown on its E. coli ATCC15597 host. Log-phase host bacteria for bacteriophage propagation were grown in tryptic soy broth (TSB, Sigma Chemicals) on an orbital shaker at room temperature, until turbid. Before use, 100 µL of culture was inoculated into fresh TSB-containing 0.0025% CaCl₂. The cultures were incubated in a 37 $^\circ\text{C}$ shaking water bath for 4 h, until the log phase was reached. Fresh bacteriophages were cultured from freezer stocks. Log-phase host bacteria and phages were mixed at a multiplicity of infection of approximately 1 in 5 mL TSB. The culture was kept on ice for 15 min to facilitate adsorption of the phages to the host cells, then it was incubated overnight at 37 °C. The resulting phage culture was filtered through a 0.2µm cellulose acetate syringe filter to remove host bacteria and then stored at 4 °C. Typical yields were 1 \times 10 10 pfu/mL. Culturable counts of phage were performed by mixing 100 μ L of phage suspension and 100 μ L of host culture in 4 mL molten TSB top agar (containing 0.7% agar). The top agar was vortexed gently, then poured on TSB plates; the plates were incubated at 37 °C. Bacteriophages from freeze stocks were diluted into buffer (30 mM Tris, 150 mM KCl, pH 8.3) to a final population density of approximately 1 \times 10 9 pfu/mL. Dilutions were prepared in phosphate-buffered saline solution. Initial as well as post-exposure culturable counts were performed in triplicate. The counts were divided by the mean unexposed control counts to normalize the data and then log-transformed.

tert-Butyl N-{2-[9-(2-trifluoromethoxyacridinyl)amino]ethyl} carbamate (**9**)

A mixture of 9-chloro-2-trifluoromethoxyacridine (1) (2.00 g, 6.7 mmol) and phenol (10.0 g, 0.1 mol) was stirred at $90^{\circ}C$

for 30 min; 2 (1.18 g, 7.4 mmol) was added, and stirring at this temperature continued for another 15 min. The product was purified by chromatography (silica gel, methanol/ethyl acetate 1:4) to afford 9 (1.47 g, 52%) as a red, highly viscous oil. UV-vis (methanol): λ_{max} (log ϵ) = 284 nm (4.68). IR (film): v = 3273w, 2981m, 1703m, 1652m, 1634m, 1592s, 1533*s*, 1407*m*, 1368*m*, 1334*w*, 1261*s*, 1215*s*, 1166*s*, 1044*w*, 1012 w cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.14 (d, ³J_{H,H} = 9.55 Hz, 1H, H-C(4)), 8.12 (s, 1H, H-C(1)), 7.91 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 7.75 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.41–7.36 (m, 2H, H-C(3,6)), 7.11 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ³*J*_{H,H} = 6.74 Hz, 1H, H-C(7)), 6.33 (*br s*, 1H, NH), 4.02–3.98 (m, 2H, CH₂(1')), 3.68-3.62 (m, 2H, CH₂(2')), 1.45 (s, 9H, ^tBu). ¹³C NMR (100 MHz, CDCl₃): δ = 157.8 (quart.), 155.1 (C=O), 143.8 (quart.), 142.0 (quart.), 140.1 (quart.), 132.9 (CH), 127.0 (CH), 124.6 (CH), 123.8 (CH), 123.2 (CH), 121.6 (CH), 120.5 (q, ${}^{1}J_{C,F}$ = 257.4 Hz, OCF₃), 116.2 (CH), 113.0 (quart.), 112.8 (quart.), 80.4 (quart., ^tBu), 51.2 (CH₂(1')), 40.4 $(CH_2(2'))$, 28.4 $(CH_3, {}^{t}Bu)$. ${}^{19}F$ NMR (188 MHz, $CDCI_3$): $\delta = -58.7$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 366 (10%) [(M-ibutene)H]+, 422 (100%) [MH]+. Analysis for C₂₁H₂₂F₃N₃O₃ (421.42): C 59.85; H 5.26; N 9.97; found: C 59.64; H 5.37; N 9.81.

tert-Butyl N-{3-[9-(2-trifluoromethoxyacridinyl)amino]propyl} carbamate (10)

As described for 9, from 1 (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and 3 (1.42 g, 8.2 mmol), 10 (1.23 g, 42%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} $(\log \varepsilon) = 284 \text{ nm} (4.71)$. IR (film): v = 3441s, 2980*m*, 1690*m*, 1630m, 1568s, 1524m, 1444w, 1392w, 1368m, 1336w, 1286*s*, 1262*s*, 1216*m*, 1169*m*, 1084*w*, 1020*w* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.21 (*d*, ³*J*_{H,H} = 9.55 Hz, 1H, H-C(4)), 8.10 (*s*, 1H, H-C(1)), 8.08 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 8.07 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.66 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(6)), 7.52 (dd, ${}^{3}J_{H,H} = 9.55$ Hz, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(3)), 7.39 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{\text{H,H}} = 6.64$ Hz, 1H, H-C(7)), 6.55 (br s, 1H, NH), 4.78 (br s, 1H, NH), 3.78–3.75 (m, 2H, CH₂(1')), 3.44–3.41 (m, 2H, 2H, 2H) CH₂(3')), 1.92-1.86 (m, 2H, CH₂(2')), 1.50 (s, 9H, ^tBu). ¹³C NMR (100 MHz, $CDCl_3$): $\delta = 157.2$ (quart.), 152.1 (C=O), 148.9 (quart.), 147.5 (quart.), 144.1 (quart.), 130.1 (2 × CH), 124.5 (2 \times CH), 123.5 (CH), 122.8 (CH), 120.5 (q, ${}^{1}J_{C,F}$ = 256.7 Hz, OCF₃), 117.1 (quart.), 116.5 (quart.), 114.2 (CH), 80.1 (quart., ^tBu), 46.5 (CH₂(1')), 37.4 (CH₂(3')), 32.1 (CH₂(2')), 28.4 (CH₃, ^tBu). ¹⁹F NMR (188 MHz, CDCl₃): δ = -58.5 (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 380 (20%) [(M-ⁱbutene)H]+, 436 (100%) [MH]+. Analysis for $C_{22}H_{22}F_3N_3O_3$ (435.45): C 60.68; H 5.56; N 9.65; found: C 60.41; H 5.74; N 9.51.

tert-Butyl N-{4-[9-(2-trifluoromethoxyacridinyl)amino]butyl} carbamate (11)

As described for **9**, from **1** (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and **4** (1.26 g, 6.7 mmol), **11** (2.09 g, 69%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} (log ε) = 286 nm (4.61). IR (film): v = 3380*m*, 2979*m*, 1699*s*, 1649*m*, 1596*s*, 1535*s*, 1407*m*, 1366*m*, 1260*s*, 1212*s*, 1162*s*, 1005*m* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.04 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 7.96 (*s*, 1H, H-C(1)), 7.83 (*d*, ³*J*_{H,H} = 9.55 Hz, 1H, H-C(4)), 7.74 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(5)), 7.45 (*dd*, ³*J*_{H,H} = 8.72 Hz, ³*J*_{H,H} = 2.08 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 8.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 8.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 6.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.15 (*dd*, ³*J*_{H,H} = 3.72 Hz, ³*J*_{H,H} = 3.64 Hz, 1H, H-C(3)), 7.1

574 Csuk et al.

CH₂(4')), 1.97–1.88 (*m*, 2H, CH₂(2')), 1.71–1.63 (*m*, 2H, CH₂(3')), 1.43 (*s*, 9H, [†]Bu). ¹³C NMR (100 MHz, CDCl₃): δ = 156.2 (quart.), 155.3 (C=O), 143.5 (quart.), 140.7 (quart.), 139.3 (quart.), 133.2 (CH), 127.1 (CH), 124.6 (CH), 123.1 (CH), 122.6 (CH), 120.5 (*q*, ¹J_{C,F} = 258.6 Hz, OCF₃), 120.4 (CH), 116.6 (CH), 112.6 (quart.), 112.3 (quart.), 79.2 (quart., ¹Bu), 48.3 (CH₂(1')), 39.9 (CH₂(4')), 28.4 (CH₃, ¹Bu), 27.4 (CH₂), 27.2 (CH₂). ¹⁹F NMR (188 MHz, CDCl₃): δ = -58.7 (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 394 (14%) [(M-¹butene)H]⁺, 450 (100%) [MH]⁺. Analysis for C₂₃H₂₆F₃N₃O₃ (449.48): C 61.46; H 5.83; N 9.35; found: C 61.32; H 5.99; N 9.21.

tert-Butyl N-{5-[9-(2-trifluoromethoxyacridinyl)amino]pentyl} carbamate (12)

As described for 9, from 1 (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and 5 (1.49 g, 7.4 mmol), 12 (2.12 g, 68%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} $(\log \varepsilon) = 282 \text{ nm} (4.69)$. IR (film): v = 3439s, 2934w, 1630m, 1508*w*, 1367*w*, 1261*s*, 1218*m*, 1165*m* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.07 (*d*, ³*J*_{H,H} = 9.55 Hz, 1H, H-C(4)), 8.05 $(d, {}^{3}J_{H,H} = 8.72 \text{ Hz}, 1\text{H}, \text{H-C}(8)), 8.03 (d, {}^{3}J_{H,H} = 8.72 \text{ Hz}, 1\text{H},$ H-C(5)), 7.92 (d, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(1)), 7.67 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(6)), 7.51 (dd, ${}^{3}J_{H,H} = 9.55$ Hz, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(3)), 7.40 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.05 (br s, 1H, H-C(7)), 5.05 (br s, 2H, 2H, 2H) (dd, 2 1H, NH), 4.53 (br s, 1H, NH), 3.79-3.74 (m, 2H, CH₂(1')), 3.15-3.08 (m, 2H, CH₂(5')), 1.84-1.76 (m, 2H, CH₂(2')), 1.54-1.42 (*m*, 4H, 2 × CH₂(3',4')), 1.41 (*s*, 9H, ^tBu). ¹³C NMR (100 MHz, CDCl₃): δ = 155.9 (C=O), 151.2 (quart.), 149.1 (quart.), 147.5 (quart.), 144.0 (quart.), 131.6 (CH), 130.1 (CH), 129.4 (CH), 124.4 (CH), 123.9 (CH), 121.9 (CH), 120.5 (q, ¹ $J_{C,F}$ = 256.6 Hz, OCF₃), 116.7 (quart.), 115.9 (quart.), 113.9 (CH), 79.2 (quart., ^tBu), 50.7 (CH₂(1')), 40.2 (CH₂(5')), 31.3 (CH₂), 29.9 (CH₂), 28.4 (CH₃, ^tBu), 24.1 (CH₂). ¹⁹F NMR (188 MHz, CDCl₃): $\delta = -58.5$ (OCF₃). MS (ESI, 4.1 kV, 8 μ L/min, N₂, methanol): 408 (12%) [(M-ibutene)H]⁺, 464 (100%) [MH]⁺. Analysis for C₂₄H₂₈F₃N₃O₃ (463.50): C 62.19; H 6.09; N 9.07; found: C 62.00; H 6.23; N 8.95.

tert-Butyl N-{6-[9-(2-trifluoromethoxyacridinyl)amino]hexyl} carbamate (13)

As described for 9, from 1 (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and 6 (1.60 g, 7.4 mmol), 13 (1.24 g, 39%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} $(\log \epsilon) = 287 \text{ nm} (4.70)$. IR (film): v = 3358m, 3009m, 2934s, 2860m, 1692s, 1619m, 1561s, 1509s, 1476s, 1392s, 1366s, 1258*s*, 1167*s*, 1022*m* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.08 (d, ${}^{3}J_{H,H} = 9.55$ Hz, 1H, H-C(4)), 8.06 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 8.05 (*d*, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.94 (*s*, 1H, H-C(1)), 7.67 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(6)), 7.51 (*dd*, ${}^{3}J_{H,H} = 9.55$ Hz, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(3)), 7.39 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.15 (br s, 1H, NH), 4.51 (br s, 1H, NH), 3.79-3.74 (m, 2H, CH₂(1')), 3.13-3.05 (m, 2H, CH₂(6')), 1.81-1.73 (m, 2H, CH₂(2')), 1.50–1.32 (*m*, 15H, ^tBu, $3 \times CH_2(3',4',5')$). ¹³C NMR (100 MHz, CDCl₃): δ = 155.9 (C=O), 151.2 (quart.), 149.2 (quart.), 147.5 (quart.), 143.9 (quart.), 131.6 (CH), 130.2 (CH), 129.5 (CH), 124.4 (CH), 123.8 (CH), 121.9 (CH), 120.6 $(q, {}^{1}J_{C,F} = 254.6 \text{ Hz}, \text{ OCF}_{3}), 116.8 (quart.), 115.8$ (quart.), 113.9 (CH), 79.1 (quart., 'Bu), 50.5 (CH₂(1')), 40.2 (CH₂(6')), 31.6 (CH₂), 30.1 (CH₂), 28.5 (CH₃, ^tBu), 26.4 (CH_2) , 26.3 (CH_2) . ¹⁹F NMR (188 MHz, CDCl₃): $\delta = -58.5$

Arch. Pharm. Pharm. Med. Chem. 2004, 337, 571-578

(OCF₃). MS (ESI, 4.1 kV, 8 μ L/min, N₂, methanol): 378 (4%) [(M-Boc)H]⁺, 422 (12%) [(M-ⁱbutene)H]⁺, 478 (100%) [MH]⁺. Analysis for C₂₅H₃₀F₃N₃O₃ (477.53): C 62.88; H 6.33; N 8.80; found: C 62.71; H 6.43; N 8.75.

tert-Butyl N-{7-[9-(2-trifluoromethoxyacridinyl)amino]heptyl} carbamate (14)

As described for $\boldsymbol{9},$ from $\boldsymbol{1}$ (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and 7 (1.70 g, 7.4 mmol), 14 (1.59 g, 48%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} $(\log \epsilon) = 286 \text{ nm} (4.71)$. IR (film): v = 3425s, 2930s, 2856s, 1690*s*, 1632*s*, 1591*s*, 1566*s*, 1528*s*, 1502*s*, 1391*m*, 1365*m*, 1276*m*, 1247*s*, 1170*s*, 1030*m* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.09 (*d*, ³*J*_{H,H} = 9.55 Hz, 1H, H-C(4)), 8.06 (*d*, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 8.03 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.92 (d, ${}^{4}J_{H,H}$ = 2.08 Hz, 1H, H-C(1)), 7.68 (dd, ¹³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(6)), 7.52 (*dd*, ³ $J_{H,H} = 9.55$ Hz, ⁴ $J_{H,H} = 2.08$ Hz, 1H, H-C(3)), 7.41 (*dd*, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ $J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 5.00 (*br* s, ³ $J_{H,H} = 8.72$ Hz, ³ 1H, NH), 4.47 (br s, 1H, NH), 3.80-3.75 (m, 2H, CH₂(1')), 3.11-3.03 (m, 2H, CH₂(7')), 1.81-1.73 (m, 2H, CH₂(2')), 1.47-1.25 (*m*, 17H, ^tBu, $4 \times CH_2(3'-6')$). ¹³C NMR (100 MHz, $CDCl_3$): $\delta = 155.9$ (C=O), 151.2 (quart.), 149.3 (quart.), 147.7 (quart.), 144.0 (quart.), 131.9 (CH), 130.1 (CH), 129.8 (CH), 124.4 (CH), 123.9 (CH), 121.8 (CH), 120.5 $(q, {}^{1}J_{C,F} =$ 256.4 Hz, OCF₃), 116.7 (quart.), 115.9 (quart.), 113.8 (CH), 79.0 (quart., ^tBu), 50.8 (CH₂(1')), 40.5 (CH₂(7')), 31.7 (CH₂), 30.0 (CH₂), 29.0 (CH₂), 28.5 (CH₃, ^tBu), 26.8 (CH₂), 26.6 (CH₂). ¹⁹F NMR (188 MHz, CDCl₃): $\delta = -58.5$ (OCF₃). MS (ESI, 4.1 kV, 8 μL/min, N₂, methanol): 392 (8%) [(M-Boc)H]+, 436 (15%) [(M-butene)H]+, 492 (100%) [MH]+. Analysis for C₂₆H₃₂F₃N₃O₃ (491.56): C 63.53; H 6.56; N 8.55; found: C 63.41; H 6.71; N 8.39.

tert-Butyl N-{8-[9-(2-trifluoromethoxyacridinyl)amino]octyl} carbamate (15)

As described for 9, from 1 (2.0 g, 6.7 mmol), phenol (10.0 g, 0.1 mol) and 8 (2.71 g, 11.1 mmol), 15 (3.09 g, 61%) was obtained as a red, highly viscous oil. UV-vis (methanol): λ_{max} $(\log \epsilon) = 286 \text{ nm} (4.76)$. IR (film): v = 3346m, 2930s, 2857m, 1694s, 1633m, 1564s, 1520s, 1392m, 1366s, 1255s, 1165s, 1041*m* cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ = 8.05 (*d*, ³*J*_{H,H} = 9.55 Hz, 1H, H-C(4)), 8.03 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 8.02 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.92 (d, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(1)), 7.65 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(6)), 7.50 (*dd*, ${}^{3}J_{H,H} = 9.55$ Hz, ${}^{4}J_{H,H} = 2.08$ Hz, 1H, H-C(3)), 7.38 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.64$ Hz, 1H, H-C(7)), 4.49 (*br s*, 1H, NH), 3.80–3.75 (*m*, 2H, CH₂(1')), 3.10–3.03 (*m*, 2H, CH₂(8')), 1.82–1.74 (*m*, 2H, CH₂(2')), 1.46–1.38 (*m*, 13H, 'Bu, 2 × CH₂(3',7')), 1.33–1.23 (*m*, 6H, 3 ± CH₂(4',5',6')). ¹³C NMR (100 MHz, CDCl₃): δ = 155.9 (C=O), 151.2 (quart.), 149.3 (quart.), 147.6 (quart.), 144.0 (quart.), 131.8 (CH), 130.1 (CH), 129.7 (CH), 124.5 (CH), 123.9 (CH), 121.8 (CH), 120.7 (q, ${}^{1}J_{C,F} = 256.7 \text{ Hz}$, OCF₃), 116.7 (quart.), 115.9 (quart.), 113.8 (CH), 79.0 (quart., ^tBu), 50.8 (CH₂(1')), 40.6 (CH₂(8')), 31.7 (CH₂), 30.1 (CH₂), 29.2 (CH₂), 29.1 (CH₂), 28.5 (CH₃, ^tBu), 26.8 (CH₂), 26.7 (CH₂). ¹⁹F NMR (188 MHz, CDCl₃): $\delta = -58.5$ (OCF₃). MS (ESI, 4.1 kV, 8 μL/min, N₂, methanol): 406 (4%) [(M-Boc)H]⁺, 450 (10%) [(M-ⁱbutene)H]⁺, 506 (100%) [MH]⁺. Analysis for C₂₈H₃₄F₃N₃O₃ (517.60): C 64.98; H 6.62; N 8.12; found: C 64.81; H 6.85; N 7.99.

Arch. Pharm. Pharm. Med. Chem. 2004, 337, 571–578

 N^{1} -[9-(2-Trifluoromethoxyacridinyl)-ethane-1,2-diamine bishydrochloride (**16**)

A solution of 9 (1.41 g, 3.3 mmol) in methanol (50 mL) containing aq. hydrochloric acid (10%, 25 mL) was stirred at room temperature for 16 h. The solvents were removed under reduced pressure, and 16 (1.29 g, 98%) was obtained as a yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 284 nm (4.59). IR (KBr): v = 3423s, 1592m, 1534m, 1474m, 1259*m*, 1165*m* cm⁻¹. ¹H NMR (400 MHz, D_2O): δ = 8.12 (*d*, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 8.07 (d, ${}^{4}J_{H,H} = 1.97$ Hz, 1H, H-C(1)), 7.82 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(7)), 7.75 (*dd*, ${}^{3}J_{H,H} = 9.34$ Hz, ${}^{4}J_{H,H} = 1.97$ Hz, 1H, H-C(3)), 7.61 (d, ${}^{3}J_{H,H} = 9.34$ Hz, 1H, H-C(4)), 7.53 (d, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(5)), 7.44 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(6)), 4.34–4.29 (*m*, 2H, CH₂(1')), 3.47–3.43 (*m*, 2H, 2H, 2H, 2H, 2H) CH₂(2')). ¹³C NMR (100 MHz, D₂O): δ = 157.5 (quart.), 144.3 (quart.), 139.3 (quart.), 137.1 (quart.), 136.0 (CH), 129.4 (CH), 124.8 (2 \pm CH), 120.7 (CH), 120.3 (q, 1 $J_{C,F}$ = 257 Hz, OCF₃), 118.4 (CH), 116.2 (CH), 112.2 (quart.), 111.5 (quart.), 45.8 (CH₂(1')), 38.5 (CH₂(2')). ¹⁹F NMR (188 MHz, D₂O): δ = -58.8 (OCF₃). MS (ESI, 4.1 kV, 8 μL/min, N₂, methanol): 322 (100%) [MH]+.

N^{1} -[9-(2-Trifluoromethoxyacridinyl)]-propane-1,3-diamine bishydrochloride (17)

As described for 9, from 10 (1.18 g, 2.7 mmol), 17 (1.04 g, 94%) was obtained as a yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 280 nm (4.55). IR (KBr): ν = 3418s, 2928s, 1628s, 1594s, 1537m, 1482s, 1400m, 1367m, 1262s, 1204*s*, 1165*s* cm⁻¹. ¹H NMR (400 MHz, D_2O): δ = 7.96 (*d*, ${}^{3}J_{H,H} = 8.72$ Hz, 1H, H-C(8)), 7.89 (s, 1H, H-C(1)), 7.70 (dd, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(7)), 7.64 (d, ${}^{3}J_{H,H} =$ 9.34 Hz, 1H, H-C(3)), 7.40 (d, ${}^{3}J_{H,H} = 9.34$ Hz, 1H, H-C(4)), 7.33 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(6)), 7.32 $(d, {}^{3}J_{H,H} = 8.72 \text{ Hz}, 1\text{H}, \text{H-C}(5)), 3.95-3.89 (m, 2\text{H}, \text{CH}_{2}(1'))$ 3.02-2.97 (m, 2H, CH₂(3')), 2.17-2.09 (m, 2H, CH₂(2')). ¹³C NMR (100 MHz, D_2O): δ = 157.0 (quart.), 144.0 (quart.), 139.0 (quart.), 137.1 (quart.), 136.8 (CH), 129.3 (CH), 124.5 (CH), 124.1 (CH), 120.5 (CH), 120.3 (q, 1J_{C.F} = 258 Hz, OCF₃), 118.2 (CH), 116.4 (CH), 111.8 (quart.), 111.4 (quart.), 45.9 (CH₂(1')), 36.9 (CH₂(3')), 27.0 (CH₂(2')). ¹⁹F NMR (188 MHz, D_2O): $\delta = -58.8$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 336 (100%) [MH]⁺.

N¹-[9-(2-Trifluoromethoxyacridinyl)]-butane-1,4-diamine bishydrochloride (**18**)

As described for **9**, from **11** (1.50 g, 3.3 mmol), **18** (1.39 g, 99%) was obtained as a yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 285 nm (4.52). IR (KBr): v = 3427*s*, 2929*s*, 1631*s*, 1596*s*, 1535*m*, 1477*m*, 1366*w*, 1261*s*, 1207*s*, 1162*s* cm⁻¹. ¹H NMR (400 MHz, D₂O): δ = 8.08 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 7.99 (*s*, 1H, H-C(1)), 7.77 (*dd*, ³*J*_{H,H} = 9.72 Hz, ³*J*_{H,H} = 6.95 Hz, 1H, H-C(7)), 7.70 (*d*, ³*J*_{H,H} = 9.34 Hz, 1H, H-C(3)), 7.55 (*d*, ³*J*_{H,H} = 9.34 Hz, 1H, H-C(6)), 7.37 (*d*, ³*J*_{H,H} = 8.72 Hz, ³*J*_{H,H} = 6.95 Hz, 1H, H-C(7)), 7.70 (*d*, ²*H*_C(*t*)), 2.92–2.87 (*m*, 2H, CH₂(4')), 1.86–1.78 (*m*, 2H, CH₂(1')), 2.92–2.87 (*m*, 2H, CH₂(4')), 1.86–1.78 (*m*, 2H, CH₂(2')), 1.68–1.58 (quart.), 143.8 (quart.), 138.4 (quart.), 136.7 (quart.), 135.7 (CH), 129.1 (CH), 124.6 (CH), 120.3 (CH), 120.3 (*q*, 1*J*_{C,F} = 258 Hz, OCF₃), 117.8 (CH₂), 24.3 (CH₂). ¹⁹F NMR

(188 MHz, D₂O): δ = -58.8 (OCF₃). MS (ESI, 4.1 kV, 8 $\mu L/$ min, N₂, methanol): 350 (100%) [MH]+.

 N^{1} -[9-(2-Trifluoromethoxyacridinyl)]-pentane-1,5-diamine bishydrochloride (**19**)

As described for 9, from 12 (2.02 g, 4.4 mmol), 19 (1.86 g, 98%) was obtained as yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 284 nm (4.49). IR (KBr): v = 3418*s*, 2966s, 1629m, 1594s, 1538m, 1485s, 1363w, 1258s, 1207s, 1165*s* cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ = 8.55 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 8.51 (*s*, 1H, H-C(1)), 7.99 (*dd*, ³*J*_{H,H} = 8.72 Hz, ³J_{H,H} = 6.95 Hz, 1H, H-C(7)), 7.95-7.92 (*m*, 2H, 2 \pm H-C(4,5)), 7.85 (*d*, ³*J*_{H,H} = 9.34 Hz, 1H, H-C(3)), 7.60 (*dd*, ${}^{3}J_{H,H} = 8.72$ Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(6)), 4.21–4.17 (m, 2H, CH₂(1')), 2.98-2.94 (m, 2H, CH₂(5')), 2.10-2.00 (m, 2H, CH₂(2')), 1.81-1.70 (m, 2H, CH₂(4')), 1.61-1.54 (m, 2H, CH₂(3')). ¹³C NMR (125 MHz, CD₃OD): δ = 159.4 (quart.), 146.1 (quart.), 141.1 (quart.), 138.9 (quart.), 136.9 (CH), 130.3 (CH), 129.9 (CH), 129.2 (CH), 126.3 (CH), 122.0 (q, 1J_{C,F} = 257 Hz, OCF₃), 122.1 (CH), 119.7 (CH), 113.2 (quart.), 113.0 (quart.), 50.2 ($CH_2(1')$), 40.5 ($CH_2(5')$), 29.9 (CH_2), 28.1 (CH_2), 24.7 (CH_2). ¹⁹F NMR (188 MHz, CD_3OD): δ = -60.1 (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 364 (100%) [MH]+.

N^{1} -[9-(2-Trifluoromethoxyacridinyl)]-hexane-1,6-diamine bishydrochloride (**20**)

As described for 9, from 13 (1.19 g, 2.5 mmol), 20 (1.09 g, 98%) was obtained as a yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 284 nm (4.60). IR (KBr): ν = 3445*s*, 2936s, 1629m, 1595s, 1538m, 1484m, 1363w, 1260s, 1208s, 1163*s* cm⁻¹. ¹H NMR (400 MHz, D₂O): δ = 7.96 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 7.85 (s, 1H, H-C(1)), 7.72 (dd, ³J_{H,H} = 8.72 Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(7)), 7.66 (*d*, ${}^{3}J_{H,H} = 9.34$ Hz, 1H, H-C(3)), 7.44 (*d*, ${}^{3}J_{H,H} = 9.34$ Hz, 1H, H-C(4)), 7.37 $(d, {}^{3}J_{H,H} = 8.72 \text{ Hz}, 1\text{H}, \text{H-C(5)}), 7.33 (dd, {}^{3}J_{H,H} = 8.72 \text{ Hz},$ ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(6)), 3.79-3.73 (*m*, 2H, CH₂(1')), 2.88-2.82 (m, 2H, CH₂(6')), 1.76-1.68 (m, 2H, CH₂(2')), 1.57-1.50 (m, 2H, CH₂(5')), 1.34-1.26 (m, 4H, CH₂(3',4')). ¹³C NMR (125 MHz, D_2O): δ = 156.5 (quart.), 135.6 (CH), 129.1 (CH), 120.3 (CH), 120.2 (q, $1J_{C,F} = 258$ Hz, OCF₃), 122.1 (CH), 118.0 (CH), 48.5 (CH₂(1')), 39.3 (CH₂(6')), 28.7 (CH₂), 26.6 (CH₂), 25.4 (CH₂), 25.2 (CH₂). ¹⁹F NMR (188 MHz, D₂O): $\delta = -58.8$ (OCF₃). MS (ESI, 4.1 kV, 8 μ L/min, N₂, methanol): 378 (100%) [MH]+.

N¹-[9-(2-Trifluoromethoxyacridinyl)]-heptane-1,7-diamine bishydrochloride (**21**)

As described for **9**, from **14** (1.54 g, 3.1 mmol), **21** (1.41 g, 97%) was obtained as a yellow, amorphous soild. UV-vis (methanol): λ_{max} (log ε) = 286 nm (4.62). IR (KBr): v = 3421*m*, 2930*s*, 1629*m*, 1596*s*, 1540*m*, 1477*m*, 1367*w*, 1257*s*, 1212*s*, 1156*s* cm⁻¹. ¹H NMR (400 MHz, D₂O): δ = 7.95 (*d*, ³J_{H,H} = 8.72 Hz, 1H, H-C(8)), 7.84 (*s*, 1H, H-C(1)), 7.72 (*dd*, ³J_{H,H} = 8.72 Hz, ³J_{H,H} = 6.95 Hz, 1H, H-C(7)), 7.66 (*d*, ³J_{H,H} = 9.34 Hz, 1H, H-C(3)), 7.45 (*d*, ³J_{H,H} = 9.34 Hz, 1H, H-C(4)), 7.37 (*d*, ³J_{H,H} = 8.72 Hz, 1H, H-C(5)), 7.33 (*dd*, ³J_{H,H} = 8.72 Hz, 1H, H-C(6)), 3.77-3.72 (*m*, 2H, CH₂(1')), 2.87-2.82 (*m*, 2H, CH₂(6')), 1.30-1.22 (*m*, 6H, 3 × CH₂(3'-5')). ¹³C NMR (100 MHz, D₂O): δ = 156.3 (quart.), 135.6 (CH), 129.1 (CH), 120.4 (CH), 120.2 (*q*, 1J_{C,F} = 257

Hz, OCF₃), 118.0 (CH), 48.6 (CH₂(1')), 39.6 (CH₂(7')), 29.0 (CH₂), 28.0 (CH₂), 27.8 (CH₂), 25.9 (CH₂), 25.7 (CH₂). ¹⁹F NMR (188 MHz, D₂O): δ = -58.9 (OCF₃). MS (ESI, 4.1 kV, 8 μL/min, N₂, methanol): 392 (100%) [MH]⁺.

N¹-[9-(2-Trifluoromethoxyacridinyl)]-octane-1,8-diamine bishydrochloride (**22**)

As described for 9, from 30 (2.99 g, 5.9 mmol), 22 (2.6 g, 92%) was obtained as a yellow, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 285 nm (4.56). IR (KBr): ν = 3424*m*, 2928s, 1629m, 1597s, 1540m, 1487s, 1366w, 1256s, 1212s, 1162*s* cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ = 8.53 (*d*, ³*J*_{H,H} = 8.72 Hz, 1H, H-C(8)), 8.47 (s, 1H, H-C(1)), 7.99 (dd, ³J_{H,H} = 8.72 Hz, ${}^{3}J_{H,H} = 6.95$ Hz, 1H, H-C(7)), 7.95 (d, ${}^{3}J_{H,H} = 9.34$ Hz, 1H, H-C(4)), 7.92 (*dd*, ${}^{3}J_{H,H} = 9.34$ Hz, ${}^{4}J_{H,H} = 2.28$ Hz, 1H, H-C(3)), 7.85 (d, ${}^{3}J_{H,H}$ = 8.72 Hz, 1H, H-C(5)), 7.59 (dd, ${}^{3}J_{H,H} = 8.72 \text{ Hz}, {}^{3}J_{H,H} = 6.95 \text{ Hz}, 1\text{H}, \text{H-C(6)}, 4.17-4.12 (m, 100)$ 2H, CH₂(1')), 2.93-2.88 (m, 2H, CH₂(8')), 2.05-1.97 (m, 2H, CH₂(2')), 1.70-1.62 (m, 2H, CH₂(7')), 1.54-1.38 (m, 6H, $4 \times CH_2(3'-6')$). ¹³C NMR (100 MHz, CD₃OD): $\delta = 159.2$ (quart.), 136.7 (CH), 130.2 (CH), 125.2 (CH), 122.0 (CH), 121.9 (q, $1J_{C,F} = 257$ Hz, OCF₃), 119.6 (CH), 50.5 (CH₂(1')), 40.8 (CH₂(8')), 30.5 (CH₂), 30.0 (2 \pm CH₂), 28.5 (CH₂), 27.7 (CH₂), 27.4 (CH₂). ¹⁹F NMR (188 MHz, CD₃OD): $\delta = -60.4$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 406 (100%) [MH]+.

2-((2-{[2-(9-{2-Trifluoromethoxyacridinyl}amino)ethyl]amino}-2-oxoethyl){2-[(2-{[2-(9-{2-trifluoromethoxyacridinyl}amino)ethyl]amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**23**)

A solution of 16 (304 mg, 0.77 mmol) in dry DMF (10 mL) containing triethylamine (3 mL) was stirred at room temperature for 10 min; EDTA dianhydride (99 mg, 0.39 mmol) was added, and stirring was continued at room temperature for another 12 h. After addition of acetone (10 mL) and hexane (40 mL), the crude product was filtered off and dissolved in methanol (15 mL) containing aq. hydrochloric acid (10%, 0.5 mL). The solvents were removed in vacuo, and the product was purified by chromatography (silica gel, methanol/acetonitrile/ammonia 70 : 25 : 5) to afford 23 (80 mg, 23%) as an amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 280 nm (4.91). IR (KBr): v = 3266m, 1590s, 1479m, 1435m, 1403m, 1332m, 1255s, 1216s, 1160s cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): δ = 8.51 (s, 2H, 2 × H-C(1)), 8.50 (d, ${}^{3}J_{HH} = 8.64$ Hz, 2H, 2 × H-C(8)), 8.00-7.95 (m, 6H, 6 × H-C(3,4,7)), 7.83 (d, ${}^{3}J_{H,H} = 8.64$ Hz, 2H, 2 × H-C(5)), 7.53–7.49 (m, 2H, 2 \pm H-C(6)), 4.16–4.13 (m, 4H, 2 \times CH₂(1')), 3.87 (*s*, 4H, 2 × CH₂(2")), 3.79 (*s*, 4H, 2 × CH₂(3")), 3.66-3.61 (*m*, 4H, 2 × CH₂(2')), 3.25 (*s*, 4H, 2 × CH₂(1")). ¹³C NMR (125 MHz, DMSO-D₆/D₂SO₄): δ = 169.7 (C=O), 168.48 (C=O), 168.44 (quart.), 157.5 (quart.), 157.4 (quart.), 143.7 (quart.), 139.5 (quart.), 138.2 (quart.), 135.7 (CH), 129.0 (CH), 124.6 (CH), 121.44 (CH), 121.35 (CH), 120.2 (q, ¹J_{C,F} = 257 Hz, OCF₃), 118.8 (CH), 118.7 (CH), 109.7 (quart.), 55.3 (CH₂(3")), 54.2 (CH₂(2")), 50.8 (CH₂(1")), 48.6 (CH₂(1')), 38.2 (CH₂(2')). ¹⁹F NMR (188 MHz, DMSO-D₆): $\delta = -57.7$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 469 (100%) [MHK]²⁺, 899 (14%) [MH]⁺, 837 (27%) [MK]⁺. Analysis for $C_{42}H_{40}F_6N_8O_8$ (898.83): C 56.13; H 4.49; N 12.47; found: C 55.97; H 4.61; N 12.32.

2-((2-{[3-(9-{2-Trifluoromethoxyacridinyl}amino)propyl]amino}-2-oxoethyl}{2-[(2-{[3-(9-{2-trifluoromethoxyacridinyl}amino)propyl] amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**24**)

As described for 23, from 17 (0.5 g, 1.23 mmol) and EDTA dianhydride (141 mg, 0.55 mmol), 24 (220 mg, 43%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 280 nm (4.68). IR (KBr): ν = 3281s, 1652s, 1574s, 1404m, 1258s, 1117m cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): $\delta = 8.50 - 8.42$ (*m*, 2H, 2 × H-C(8)), 8.43 (s, 2H, 2 × H-C(1)), 8.04–7.93 (m, 6H, 6 × H-C(3,4,7)), 7.85 $(d, {}^{3}J_{H,H} = 8.92 \text{ Hz}, 2\text{H}, 2 \times \text{H-C}(5)), 7.55-7.49 (m, 2\text{H}, 2 \times \text{H})$ H-C(6)), 4.12–4.06 (m, 4H, 2 × $CH_2(1')$), 3.91 (s, 4H, 2 × $CH_2(2'')$), 3.81 (*s*, 4H, 2 × $CH_2(3'')$), 3.32 (*s*, 4H, 2 × $CH_2(1'')$), 3.26-3.21 (m, 4H, 2 × CH₂(3')), 2.08-2.02 (m, 4H, 2 × CH₂(2')). ¹³C NMR (125 MHz, DMSO-D₆/D₂SO₄): δ = 172.3 (C=O), 169.8 (C=O), 169.3 (quart.), 166.8 (quart.), 157.6 (quart.), 157.5 (quart.), 135.6 (quart.), 138.2 (quart.), 129.0 (CH), 123.9 (CH), 121.4 (CH), 121.3 (CH), 120.2 (q, ¹J_{C,F} = 258 Hz, OCF₃), 118.8 (CH), 118.7 (CH), 55.4 (CH₂(3")), 54.4 (CH₂(2")), 50.7 (CH₂(1")), 46.7 (CH₂(1')), 36.3 (CH₂(3')), 28.7 $(CH_2(2'))$. ¹⁹F NMR (188 MHz, DMSO-D₆): $\delta = -57.7$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 483 (100%) [MHK]²⁺, 927 (10%) [MH]⁺, 965 (50%) [MK]⁺. Analysis for C₄₄H₄₄F₆N₈O₈ (926.88): C 57.02; H 4.79; N 12.09; found: C 56.91; H 4.93; N 11.88.

2-((2-{[4-(9-{2-Trifluoromethoxyacridinyl}amino)butyl]amino}-2-oxoethyl){2-[(2-{[4-(9-{2-trifluoromethoxyacridinyl}amino)butyl]amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (25)

As described for 23, from 18 (0.48 g, 1.14 mmol) and EDTA dianhydride (131 mg, 0.51 mmol), 25 (60 mg, 12%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 281 nm (4.99). IR (KBr): v = 3261m, 2929m, 1652s, 1566s, 1478m, 1395m, 1256s, 1217s, 1160s cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): $\delta = 8.50-8.45$ (*m*, 2H, 2 ± H-C(8)), 8.05-7.90 (m, 8H, 8 × H-C(1,3,4,7)), 7.87 (d, ${}^{3}J_{\rm H,H}$ = 8.73 Hz, 2H, 2 × H-C(5)), 7.55–7.50 (m, 2H, 2 × H-C(6)), 4.09–4.04 (m, 4H, 2 \times CH₂(1')), 4.07 (s, 4H, 2 \times CH₂(2")), 3.95 (s, 4H, 2 × CH₂(3")), 3.55 (s, 4H, 2 × CH₂(1")), 3.16-3.11 (*m*, 4H, 2 × CH₂(4')), 1.92-1.85 (*m*, 8H, 4 × $CH_2(2',3')$), 1.56–1.50 (*m*, 8H, 4 × $CH_2(2',3')$). ¹³C NMR $(125 \text{ MHz}, \text{DMSO-D}_6/\text{D}_2\text{SO}_4): \delta = 170.6 \text{ (C=O)}, 168.2 \text{ (C=O)},$ 165.1 (quart.), 158.1 (quart.), 157.6 (quart.), 143.8 (quart.), 139.5 (quart.), 138.2 (quart.), 129.5 (CH), 124.9 (CH), 124.8 (CH), 121.9 (CH), 121.5 (CH), 120.3 (q, ${}^{1}J_{C,F} = 257$ Hz, OCF₃), 119.2 (CH), 118.9 (CH), 111.8 (quart.), 111.6 (quart.), 55.5 (CH₂(3")), 54.3 (CH₂(2")), 50.3 (CH₂(1")), 48.6 (CH₂(1')), 38.5 (CH₂(4')), 26.3 (CH₂), 26.1 (CH₂). ¹⁹F NMR (188 MHz, DMSO- D_6): $\delta = -57.7$ (OCF₃). MS (ESI, 4.1 kV, 8 µL/min, N₂, methanol): 497 (100%) [MHK]²⁺, 955 (4%) [MH]⁺, 993 (15%) [MK]⁺. Analysis for C₄₆H₄₈F₆N₈O₈ (954.93): C 57.86; H 5.07; H 11.73; found: C 57.62; H 5.23; N 11.63.

2-((2-{[5-(9-{2-Trifluoromethoxyacridinyl}amino)pentyl]amino}-2-oxoethyl){2-[(2-{[5-(9-{2-trifluoromethoxyacridinyl} amino)pentyl]amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**26**)

As described for **23**, from **19** (0.5 g, 1.15 mmol) and EDTA dianhydride (132 mg, 0.52 mmol), **26** (80 mg, 16%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 284 nm (5.01). IR (KBr): v = 3406*m*, 2933*m*, 1565*s*, 1523*m*, 1478*m*, 1436*m*, 1397*m*, 1330*w*, 1257*s*,

Arch. Pharm. Pharm. Med. Chem. 2004, 337, 571-578

1217*s*, 1160*m* cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): $\delta = 8.69 - 8.40$ (br m, 4H, 4 × H-C(1,8)), 8.01-7.95 (m, 6H, $6 \times$ H-C(3,4,7)), 7.87 (*d*, ³J_{H,H} = 8.94 Hz, 2H, 2 × H-C(5)), 7.56-7.51 (m, 2H, 2 × H-C(6)), 4.09 (s, 4H, 2 × CH₂(2")), 4.06-4.01 (*m*, 4H, 2 × CH₂(1')), 3.97 (*s*, 4H, 2 × CH₂(3")), 3.56 (s, 4H, $2 \times CH_2(1'')$), 3.13–3.08 (m, 4H, $2 \times CH_2(5')$), 1.91-1.84 (m, 4H, 2 × CH₂(2')), 1.51-1.43 (m, 4H, 2 × CH₂(4')), 1.42-1.34 (m, 4H, 2 × CH₂(3')). ¹³C NMR (125 MHz, DMSO-D₆/D₂SO₄): δ = 169.1 (C=O), 168.2 (C=O), 165.0 (quart.), 157.6 (quart.), 157.5 (quart.), 143.8 (quart.), 139.5 (quart.), 135.7 (CH), 129.1 (CH), 124.8 (CH), 121.53 (CH), 121.43 (CH), 120.4 (q, ${}^{1}J_{C,F} = 257$ Hz, OCF₃), 118.96 (CH), 118.85 (CH), 111.8 (quart.), 111.6 (quart.), 55.5 $(CH_2(3'')),\,54.3\,(CH_2(2'')),\,50.3\,(CH_2(1'')),\,49.0\,(CH_2(1')),\,38.7\,(CH_2(5')),\,28.5\,(2\,\times\,CH_2),\,23.7\,(CH_2).$ ^{19}F NMR (188 MHz, DMSO-D₆): $\delta = -57.7$ (OCF₃). MS (ESI, 4.1 kV, 8 μ L/min, N₂, methanol): 511 (100%) [MHK]²⁺, 1021 (9%) [MK]⁺. Analysis for $C_{48}H_{52}F_6N_8O_8$ (982.99): C 58.65; H 5.33; N 11.40; found: C 58.51; H 5.56; N 11.21.

2-((2-{[6-(9-{2-Trifluoromethoxyacridinyl}amino)hexyl]amino}-2-oxoethyl){2-[(2-{[6-(9-{2-trifluoromethoxyacridinyl}amino)hexyl]amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**27**)

As described for 23, from 20 (0.5 g, 1.11 mmol) and EDTA dianhydride (128 mg, 0.5 mmol), 27 (122 mg, 24%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ϵ) = 283 nm (4.92). IR (KBr): v = 3423s, 2935m, 1647s, 1593s, 1485m, 1401m, 1364m, 1259s, 1208s, 1163s cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): δ = 8.55-8.37 (*br m*, 4H, 4 × H-C(1,8)), 8.02–7.89 (*m*, 6H, 6 × H-C(3,4,7)), 7.85 (d, ${}^{3}J_{H,H}$ = 8.57 Hz, 2H, 2 × H-C(5)), 7.52–7.47 (m, 2H, 2 × H-C(6)), 4.11 (s, 4H, 2 × CH₂(2")), 4.04-3.96 (m, 4H, 2 imes CH₂(1')), 3.99 (s, 4H, 2 imes CH₂(3")), 3.62 (s, 4H, 2 imes $CH_2(1'')$), 3.07-3.01 (m, 4H, 2 × $CH_2(6')$), 1.86-1.79 (m, 4H, 2 × CH₂(2')), 1.42–1.23 (*m*, 12H, 6 × CH₂(3'-5')). ¹³C NMR (125 MHz, DMSO-D₆/D₂SO₄): δ = 168.0 (C=O), 164.7 (C=O), 158.2 (quart.), 157.6 (quart.), 144.0 (quart.), 139.7 (quart.), 138.4 (quart.), 135.9 (CH), 129.3 (CH), 125.1 (CH), 121.73 (CH), 121.63 (CH), 120.6 (q, ¹J_{C,F} = 257 Hz, OCF₃), 119.15 (CH), 119.05 (CH), 112.0 (quart.), 111.8 (quart.), 55.7 (CH₂(3")), 54.6 (CH₂(2")), 50.4 (CH₂(1")), 49.1 (CH₂(1')), 39.0 $(CH_2(6'))$, 28.9 (2 × CH₂), 26.31 (CH₂), 26.24 (CH₂). ¹⁹F NMR (188 MHz, DMSO- D_6): $\delta = -57.8$ (OCF₃). MS (ESI, 4.1 kV, 8 μL/min, N₂, methanol): 525 (100%) [MHK]²⁺, 1049 (20%) [MK]⁺. Analysis for C₅₀H₅₆F₆N₈O₈ (1011.04): C 59.40; H 5.59; N 11.08; found: C 59.32; H 5.78; N 10.94.

2-((2-{[7-(9-{2-Trifluoromethoxyacridinyl}amino)heptyl]amino}-2-oxoethyl){2-[(2-{[7-(9-{2-trifluoromethoxyacridinyl}amino)heptyl amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**28**)

As described for **23**, from **21** (0.5 g, 1.08 mmol) and EDTA dianhydride (124 mg, 0.48 mmol), **28** (63 mg, 13%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 281 nm (5.03). IR (KBr): v = 3323s, 2936*m*, 1650*s*, 1593*s*, 1488*m*, 1399*m*, 1364*m*, 1260*s*, 1211*s*, 1160*s* cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): $\delta = 8.57-8.38$ (*br m*, 4H, 4 × H-C(1,8)), 8.07-7.95 (*m*, 6H, 6 × H-C(3,4,7)), 7.87 (*d*, ³J_{H,H} = 8.75 Hz, 2H, 2 × H-C(5)), 7.57-7.51 (*m*, 2H, 2 × H-C(6)), 4.09-4.02 (*m*, 4H, 2 × CH₂(1'')), 4.07 (*s*, 4H, 2 × CH₂(2'')), 3.94 (*s*, 4H, 2 × CH₂(3'')), 1.89-1.82 (*m*, 4H, 2 × CH₂(2'')), 1.42-1.18 (*m*, 16H, 8 × CH₂(3'-6')). ¹³C NMR (125 MHz, DMSO-D₆/D₂SO₄): $\delta = 168.2$ (C=O), 164.7

(C=O), 157.4 (quart.), 129.3 (2 × CH), 121.0 (2 × CH), 120.0 (CH), 119.15 (2 × CH), 56.0 (CH₂(3")), 55.0 (CH₂(2")), 50.5 (CH₂(1")), 49.0 (CH₂(1')), 40.3 (CH₂(7')), 28.7 (CH₂), 28.4 (2 × CH₂), 26.2 (2 × CH₂). ¹⁹F NMR (188 MHz, CD₃OD/TFA): δ = -78.3 (OCF₃). MS (ESI, 4.1 kV, 8 μ L/min, N₂, methanol): 539 (40%) [MHK]²⁺, 1077 (100%) [MK]⁺. Analysis for C₅₂H₆₀F₆N₈O₈ (1039.10): C 60.11; H 5.82; N 10.78; found: C 59.96; H 5.95; N 10.61.

2-((2-{[8-(9-{2-Trifluoromethoxyacridinyl}amino)octyl]amino}-2-oxoethyl}{2-[(2-{[8-(9-{2-trifluoromethoxyacridinyl}amino)octyl]amino}-2-oxoethyl)(carboxymethyl)amino]ethyl}amino) acetic acid (**29**)

As described for 23, from 22 (0.5 g, 1.05 mmol) and EDTA dianhydride (120 mg, 0.47 mmol), 29 (62 mg, 12%) was obtained as an orange, amorphous solid. UV-vis (methanol): λ_{max} (log ε) = 280 nm (4.93). IR (KBr): v = 3260m, 3077m, 2930s, 2856m, 1648s, 1592s, 1478m, 1399m, 1362m, 1330w, 1258s, 1216s, 1162s cm⁻¹. ¹H NMR (500 MHz, DMSO-D₆/D₂SO₄): $\delta = 8.51 - 8.40$ (*br m*, 4H, 4 × H-C(1,8)), 7.99–7.91 (*m*, 6H, 6 × H-C(3,4,7)), 7.85 (*d*, ${}^{3}J_{H,H}$ = 8.46 Hz, 2H, 2 \times H-C(5)), 7.53-7.47 (*m*, 2H, 2 \times H-C(6)), 4.10 (*s*, 4H, 2 × CH₂(2")), 4.03-3.95 (m, 4H, 2 × CH₂(1')), 3.97 (s, 4H, 2 × CH₂(3")), 3.59 (s, 4H, 2 × CH₂(1")), 3.06–3.00 (m, 4H, 2 \times CH₂(8')), 1.86–1.77 (*m*, 4H, 2 \times CH₂(2')), 1.38–1.15 (*m*, 20H, 10 × CH₂(3'-7')). ¹³C NMR (100 MHz, DMSO-D₆/D₂SO₄): δ = 169.7 (C=O), 166.8 (C=O), 157.2 (2 imes quart.), 146.3 (quart.), 135.4 (CH), 128.7 (CH), 125.1 (CH), 121.1 (CH), 121.2 (CH), 120.6 $(q, {}^{1}J_{C,F} = 257 \text{ Hz}, \text{ OCF}_{3}),$ 118.6 (CH), 118.5 (CH), 112.6 (2 \times quart.), 55.6 (CH₂(3")), 54.1 (CH₂(2")), 51.0 (CH₂(1")), 48.9 (CH₂(1')), 38.7 (CH₂(6')), 28.8 (CH₂), 28.7 (CH₂), 28.6 (2 \times CH₂), 26.3 (CH₂), 26.1 (CH₂). ¹⁹F NMR (188 MHz, DMSO-D₆): $\delta = -57.8$ (OCF₃). MS (ESI, 4.1 kV, 8 μ IL/min, N₂, methanol): 553 (100%) [MHK]²⁺, 1065 (18%) [MK]⁺. Analysis for C₅₄H₆₄F₆N₈O₈ (1067.15): C 60.78; H 6.05; N 10.50; found: C 60.61; H 6.23; N 10.43.

References

- H.-J. Neumann, H. Knoller, PCT WO 02/32875A1 [Chem. Abstr. 2002, 136, 319358].
- [2] R. Csuk, A. Barthel, C. Raschke, *Tetrahedron* 2004, 60, 5737–5750.
- [3] E. S. Endel'man, V. S. Danilenko, F. P. Trinus, P. A. Yufa, A. G. Fadeicheva, I. I. Muravov, Y. A. Fialkov, L. M. Yagupol'skii, *Pharm. Chem. J. (Engl. Transl.)* **1973**, *7*, 755–759.
- [4] P. Xu, T. Zhang, W. Wang, X. Zou, X. Zhang, Y. Fu, Synthesis 2003, 1171–1176.
- [5] G. Byk, C. Gilon, J. Org. Chem. 1992, 57, 5687-5692.
- [6] C. Haskell-Luevano, A. Rosenquist, A. Sovers, K. C. Khong, J. A. Ellman, R. D. Cone, *J. Med. Chem.* **1999**, *42*, 4380–4387.
- [7] M. Takeyama, A. Otaka, N. Fuji, *Chem. Pharm. Bull.* 1992, 40, 2199–2201.
- [8] Y. Okada, Y. Tsuda, M. Toda, K. Wanaka, U. Okamoto, A. Hijikato-Okunomija, S. Okamoto, *Chem. Pharm. Bull.* 2000, 48, 1964–1972.
- [9] M. Macchia, F. Salvetti, S. Bertini, V. di Bussolo, L. Gattuso, M. Gesi, M. Hamdan, K.-N. Klotz, T. Laragione, A.

Lucacchini, F. Minuto, *Bioorg. Med. Chem. Lett.* 2003, *11*, 3023–3026.

- [10] B. G. Jimenez, T. Klimkait, I. H. Gilbert, C. Simons, *Bioorg. Med. Chem.* 2003, *11*, 87–94.
- [11] D. J. Dupre, F. A. Robinson, J. Chem. Soc. 1945, 2, 549–551.

Arch. Pharm. Pharm. Med. Chem. 2004, 337, 571–578

- [12] E. T. Martins, H. Beruah, J. Kramarczyk, G. Saluta, J. Med. Chem. 2001, 25, 4492–4496.
- [13] R. Young, Microbiol. Rev. 1992, 56, 430-481.
- [14] M. D. Sobsey, A. Gold, M. J. Casteel, PCT WO 02/ 02153A1 [Chem. Abstr. 2002, 136, 90904].

